Press / media

As an institution of application-oriented research, the Fraunhofer Institute for Cell Therapy and Immunology IZI attaches great importance to informing customers and the public.

28.11.2025

PD Dr. Sebastian Ulbert appointed Professor of Translational Infection Immunology at Leipzig University

On November 1, 2025, PD Dr. Sebastian Ulbert, Head of the Department of Infection Research and Diagnostics and Deputy Director of the Fraunhofer Institute for Cell Therapy and Immunology IZI, was appointed Professor of Translational Infection Immunology at Leipzig University.
more info

13.10.2025

PlasmidFactory and Fraunhofer IZI join forces to advance non-viral cell and gene therapies

PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP manufacturing, aiming to accelerate non-viral cell and gene therapies for the benefit of patients.
more info

1.10.2025

Prof. Dr. Stephan Fricke appointed Chair of Clinical Immunology and Cell Therapy at Magdeburg University Hospital

Prof. Dr. Stephan Fricke, Head of the Department of Cell and Gene Therapy Development at the Fraunhofer Institute for Cell Therapy and Immunology IZI, has been appointed to the new professorship in Clinical Immunology and Cell Therapy at Magdeburg University Hospital, effective October 1, 2025. At the same time, he will also assume leadership of the Institute for Clinical Immunology and Cell Therapy at the University of Magdeburg.
more info

27.8.2025

Decentralized Manufacturing of CAR-T Cell Therapeutics

Fraunhofer IZI is part of the EU consortium EASYGEN. Coordinated by Fresenius, 18 industrial and academic partners are working together to develop an integrated and automated manufacturing platform for the decentralized production of CAR-T cell therapeutics. In this context, Fraunhofer IZI contributes its expertise in the development and manufacturing of CAR-T cell therapies as well as various other cell-based therapeutics. EASYGEN is funded by the EU under the Innovative Health Initiative Joint Undertaking (IHI JU).
more info

Archive news and press releases

RSS Newsfeed

Get the latest news about the Fraunhofer IZI. Through our RSS-feed you have the opportunity to follow all our press releases and receive them right when they are published.

Social media

 

Media library

 

Events